共查询到19条相似文献,搜索用时 140 毫秒
1.
目的:探讨治疗前血清中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)和淋巴细胞与单核细胞比值(lympho cyte to monocyte ratio,LMR)对表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs)治疗EGFR突变阳性非小细胞肺癌(non-small cell lung cancer,NSCLC)患者预后的预测价值。方法:回顾性分析112例EGFR突变阳性并接受了EGFR-TKIs治疗的Ⅳ期NSCLC患者的临床资料,根据接受者操作特征曲线(ROC)分析确定的NLR和LMR的最佳分界值,将患者分为高、低水平两组,比较不同分组之间的无进展生存时间(progression free survival,PFS)和总生存时间(overall survival,OS),通过Cox比例风险模型分析影响PFS和OS的独立预后因素。结果:根据ROC曲线,NLR=2.92,LMR=3.81作为评价的分界值。低NLR组和高NLR组的PFS分别为15.6个月和10.5个月(P<0.001),OS分别为26.9个月和19.3个月(P=0.003);高LMR组和低LMR组的PFS分别为13.4个月和11.5个月(P=0.024),OS分别为26.2个月和21.8个月(P=0.020)。通过多因素分析发现,ECOG评分和NLR是影响患者PFS和OS的独立预后因素。结论:治疗前血清NLR水平可作为预测EGFR-TKIs治疗EGFR突变阳性Ⅳ期NSCLC患者的预后因子。 相似文献
2.
3.
4.
[目的]探讨食管小细胞癌(small cell carcinoma of the esophagus,SCCE)术后中性粒细胞/淋巴细胞比值(neutrophil/lymphocyte ratio,NLR)、血小板/淋巴细胞比值(platelet/lymphocyte ratio,PLR)、淋巴细胞/单核细胞比值(lymphocyte/monocyte ratio,LMR)与临床病理特征及预后的相关性。[方法]回顾性分析河北省肿瘤医院收治的126例SCCE手术患者,分析NLR、PLR、LMR与SCCE临床病理特征及预后的关系。[结果]术后SCCE患者中NLR与肿瘤大小、局部浸润深度、淋巴结转移和TNM分期相关;PLR与局部浸润深度、淋巴结转移、远处转移和TNM分期相关;LMR与局部浸润深度、远处转移和TNM分期相关。单因素分析显示:肿瘤大小、局部浸润深度、淋巴结转移、远处转移、TNM分期、NLR、PLR和LMR水平与预后相关。多因素Cox回归分析显示:NLR、PLR、LMR、远处转移和TNM分期是SCCE患者的独立预后因素,高NLR组、高PLR组和低LMR组患者预后较差。[结论] NL... 相似文献
5.
6.
7.
8.
9.
目的 探讨营养预后指数与接受替吉奥联合阿帕替尼治疗的晚期三线结直肠癌患者的疗效的相关性。方法 回顾性收集接受阿帕替尼联合替吉奥治疗的43例三线结直肠癌患者的临床资料,计算预后营养指数(PNI)、白蛋白/球蛋白比值(AGR)、中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)以及淋巴细胞/单核细胞比值(LMR)等营养免疫评估指标,采用Cox比例风险回归模型及Kaplan-Meier生存曲线评价相关免疫营养指标对于患者生存的影响。 结果 根据总生存时间(OS)的受试者工作特征曲线 (ROC)曲线分析,PNI最佳临界值定义为47.08;单因素分析结果显示,美国东部肿瘤协作组(ECOG)评分、PNI、AGR、血红蛋白(HGB)、NLR及LMR与患者OS显著相关;多变量分析显示ECOG评分及PNI是OS的独立预后因素。低PNI患者中位生存时间(mOS)为5.70个月(95%CI=4.42~6.98),高PNI患者mOS为15.77个月(95%CI=7.43~24.1),P=0.000;低PNI的患者中位无进展生存时间(mPFS)为3.42个月(95%CI=2.31~4.53),高PNI患者mPFS为6.29个月(95%CI=4.96~7.62),P=0.003。结论 PNI在作为晚期结直肠癌接受替吉奥联合阿帕替尼三线治疗的生存预测方面具有较好临床应用价值,简单易行。 相似文献
10.
目的 探讨治疗前中性粒细胞淋巴细胞比(NLR)、淋巴细胞单核细胞比(LMR)、血小板淋巴细胞比(PLR)与乳腺癌患者临床病理特征及预后的关系。 方法 回顾性分析189例乳腺癌患者的临床资料,应用ROC曲线获得NLR、LMR、PLR的临界值。根据临界值将患者分为高低两组,分析NLR、LMR、PLR与临床病理特征及预后的相关性。结果 NLR、LMR、PLR最佳临界值分别为2.4、5.4、113。高低NLR组患者的新辅助化疗和手术治疗差异有统计学意义(均P<0.05),高低LMR组和PLR组患者在各临床病理特征方面差异无统计学意义(均P>0.05)。单因素分析结果显示,TNM临床分期、PR表达、NLR、LMR、PLR、手术以及内分泌治疗均与OS有关(均P<0.05);TNM临床分期、HER2表达、NLR、手术以及内分泌治疗均与PFS有关(均P<0.05)。多因素分析结果显示,TNM临床分期(P=0.003)和NLR(P=0.033)是OS的独立危险因素;TNM临床分期(P=0.002)和手术治疗(P=0.040)是PFS的独立影响因素。结论 治疗前NLR、LMR、PLR与乳腺癌的预后存在显著相关性,但仅NLR是独立危险因素,LMR、PLR尚不能作为独立预测因子。 相似文献
11.
目的:探讨化疗前外周血NLR和PLR与晚期NSCLC患者接受一线含铂双药化疗疗效和预后的相关性。方法:选取在我院确诊的初治晚期NSCLC患者230例,计算化疗前NLR和PLR,并根据ROC曲线图计算其截断值。分析NLR和PLR与NSCLC临床病理特征的关系。分别比较各组患者中位生存时间的差异;采用单因素及多因素 Logistic 回归对预后因素进行分析。结果:根据ROC曲线计算NLR和 PLR临界值分别为:4.5和235。外周血PLR与治疗反应显著相关(P<0.05),而NLR与治疗反应无明显相关(P>0.05)。高NLR组和低NLR组OS分别为:11个月和15.8个月(P<0.001);高PLR组和低PLR组OS分别为:12个月和15.2个月(P<0.001)。单因素和多因素结果显示,NLR和PLR是晚期NSCLC预后的独立影响因素。结论:外周血PLR一定程度上可预测化疗反应,NLR和PLR是晚期NSCLC预后的独立影响因素,治疗前评估NLR和PLR可以判断晚期NSCLC患者的预后。 相似文献
12.
目的:探讨泛免疫-炎症指数(PIV)和白蛋白-碱性磷酸酶比值(AAPR)对非小细胞肺癌伴脑转移患者的预后评估价值。方法:回顾性分析2015年12月—2022年4月在郑州大学第二附属医院初诊的102例非小细胞肺癌伴脑转移患者的病例资料,包括患者基本临床病理特征、治疗过程中头部放疗情况、基线实验室资料等,通过血常规及肝功能指标计算出PIV、AAPR、系统免疫炎症指数(SII)、中性粒细胞/淋巴细胞比值(NLR)、衍生中性粒细胞/淋巴细胞比值(dNLR)、血小板/淋巴细胞比值(PLR)、淋巴细胞/单核细胞比值(LMR),通过X-tile软件计算预测非小细胞肺癌伴脑转移患者预后的PIV和AAPR等的最佳截断值。采用χ2检验或Fisher确切概率法评估非小细胞肺癌伴脑转移患者PIV、AAPR与临床病理指标之间的相关性。采用单变量和多变量Cox比例风险回归模型,分析这些变量和临床结局之间的相关性,探讨影响非小细胞肺癌伴脑转移患者生存的因素,并通过R软件绘制生存曲线。结果:PIV、AAPR、SII、NLR、dNLR、PLR、LMR的截断值分别为221.9、0.6、1 039.4... 相似文献
13.
14.
Background and objectivesThe aim of this study was to investigate the impact of systemic immune-inflammation index (SII), platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) on the survival outcomes of patients who underwent to cytoreductive surgery (CRS) and HIPEC for ovarian peritoneal carcinomatosis.MethodsA retrospective analysis of 68 cases following surgery at our department between 2015 and 2020 was performed. Receiver Operating Characteristic (ROC) curve was used with Youden index to calculate the optimal cutoff values for SII, PLR and NLR.ResultsUnivariate analysis revealed that high preoperative values of SII, PLR and NLR were correlated with worse overall survival (OS) and disease-free survival (DFS) in these patients. In the multivariable analysis, high SII was recognized as an independent prognostic factor for OS (CI 95%: 0.002- 3.835, p = 0.097) and high PLR was recognized as an independent prognostic factor for DFS (CI 95%: 0.253–2.248, p = 0.007).ConclusionSII and PLR could be useful prognostic tools to predict outcomes of patients who underwent to CRS and HIPEC for ovarian peritoneal carcinomatosis. 相似文献
15.
N. Hirahara T. Matsubara D. Kawahara S. Nakada S. Ishibashi Y. Tajima 《European journal of surgical oncology》2017,43(2):493-501
Background
Recent studies have revealed significant relationships between the lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) and survival in various cancers. The purpose of this study was to confirm whether the LMR, NLR, and PLR have prognostic values, independent of clinicopathological criteria, in patients undergoing curative resection for esophageal cancer.Methods
The LMR, NLR and PLR were calculated in 147 consecutive patients who underwent curative esophagectomy between January 2006 and December 2014. Receiver operating characteristics (ROC) curve analysis was conducted to identify the optimal cutoff values of each biomarkers.Results
In multivariate analysis for cancer-specific survival (CSS), pTNM stage (p < 0.0001) and low LMR (p = 0.0081) were selected as independent prognostic factor. Similarly, pTNM stage(p < 0.0001) and low LMR (p = 0.0225) were found to be independent prognostic factor for overall survival (OS). There was no significant relationship between LMR, NLR and PLR and survival in patients with stage I or II, however, significant relationships between LMR and CSS or OS were observed in patients with stage III esophageal cancer.Conclusions
LMR can be used as a novel predictor of postoperative CSS and OS in patients with esophageal cancer and that it may be useful in identifying patients with a poor prognosis even after radical esophagectomy. 相似文献16.
17.
Hiroshi Kobayashi Tomotake Okuma Hiroyuki Oka Toshihide Hirai Takahiro Ohki Masachika Ikegami Ryoko Sawada Yusuke Shinoda Toru Akiyama Kenji Sato Satoshi Abe Hirotaka Kawano Takahiro Goto Sakae Tanaka 《International journal of clinical oncology / Japan Society of Clinical Oncology》2018,23(2):368-374
Background
Pazopanib is a multi-tyrosine kinase inhibitor that is used to treat advanced soft-tissue sarcoma, and its efficacy has been confirmed in several clinical trials, although no clinically useful biomarkers have been identified. In other cancers, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the lymphocyte-to-monocyte ratio (LMR) are associated with chemotherapy response and prognosis. Therefore, we aimed to evaluate the associations of pazopanib response with NLR, PLR, and LMR among patients with advanced soft-tissue sarcoma.Methods
Data regarding NLR, PLR, and LMR were obtained for 25 patients who received pazopanib for soft-tissue sarcoma. The patients were categorized according to their values for NLR (≥3.8 vs. <3.8), PLR (≥230 vs. <230), and LMR (≥2.4 vs. <2.4), and we evaluated the associations of these markers with progression-free survival and overall survival using Kaplan–Meier curves and Cox proportional models.Results
No significant differences in progression-free survival or overall survival were observed based on the pre-treatment NLR, PLR, and LMR values. However, decreased NLR values after treatment using pazopanib were independently associated with significantly prolonged progression-free survival (hazard ratio: 0.07, p = 0.001) and overall survival (hazard ratio: 0.17, p = 0.0006).Conclusions
Decreased NLR values after treatment using pazopanib may predict high efficacy and favorable outcomes among patients with advanced soft-tissue sarcoma.18.
19.
Vlad I. Nechita Nadim Al-Hajjar Emil Moi Luminia Furcea Mihaela A. Nechita Florin Graur 《Current oncology (Toronto, Ont.)》2022,29(12):9242
Our study aimed to evaluate the baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII) in relation to invasion, metastasis, and resectability for patients with gastric cancer, respectively, as predictors of death during hospitalization or surgical complications. A retrospective cohort study was conducted on 657 gastric cancer subjects. Inflammatory biomarkers were computed. The associations with tumor stage, metastasis, optimal procedure, in-hospital mortality, and surgical complications were evaluated. Subjects who underwent curative-intent surgery presented lower median NLRs (2.9 vs. 3.79), PLRs (166.15 vs. 196.76), and SIIs (783.61 vs. 1122.25), and higher LMRs (3.34 vs. 2.9) than those who underwent palliative surgery. Significantly higher NLRs (3.3 vs. 2.64), PLRs (179.68 vs. 141.83), and SIIs (920.01 vs. 612.93) were observed for those with T3- and T4-stage cancer, in comparison with those with T1- and T2-stage cancer. Values were significantly higher in the case of metastasis for the NLR (3.96 vs. 2.93), PLR (205.22 vs. 167.17), and SII (1179 vs. 788.37) and significantly lower for the LMR (2.74 vs. 3.35). After the intervention, the NLR, PLR, and SII values were higher (p < 0.01) for patients with surgical complications, and the NLR and SII values were higher for those who died during hospitalization. Higher NLRs, PLRs, SIIs, and lower LMRs were associated with a more aggressive tumor; during early follow-up, these were related to post-operative complications and death during hospitalization. 相似文献